RGCC Certified Center for Q Restrain

Q-REstrain operates through a mechanism called RNA interference (RNAi). This process involves introducing small interfering RNA (siRNA) or microRNA (miRNA) molecules into the body. These molecules bind to the messenger RNA (mRNA) of target genes, leading to their degradation and preventing the production of proteins essential for the survival or replication of pathogens or cancer cells. The therapy is autologous, meaning it is customized using the patient's own biological samples, ensuring specificity and reducing the risk of adverse reactions.

Q-REstrain has been explored for the treatment of various chronic infections and cancers. It has shown potential in targeting:

• Chronic Infections:
  • Lyme disease (Borrelia species)
  • Co-infections such as Babesia and Bartonella
  • Viral infections including Epstein-Barr Virus (EBV), Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Hepatitis B and C, Human Papillomavirus (HPV), and others
     
• Cancers:
  • Various types of cancer, with a focus on reducing circulating tumor cells (CTCs) and modulating gene expression associated with tumor growth
     

1. Diagnostic Testing: A blood sample is collected from the patient and sent to RGCC laboratories for analysis.
    
2. Oligonucleotide Design: Based on the diagnostic results, specific oligonucleotides are designed to target the identified pathogens or cancer cells.
    
3. IV Administration: The customized Q-REstrain formulation is administered intravenously, typically over a period of 90 minutes.
    
4. Duration of Action: The therapy remains active in the body for approximately 24 to 28 weeks, continuously targeting the specific genetic sequences associated with the disease.

Schedule a Q RE-strain consultation to get started